Portal de investigación
Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Michallet, M
- Sobh, M
- Hazelaar, S
- Apperley, J
- Milpied, N
- Labussiere-Wallet, H
- Blaise, D
- Foa, R
- Sierra, J
- Deconinck, E
- Angelucci, E
- Carlson, K
- Porras, RP
- Ganser, A
- Mohty, M
- Vittorio, R
- Clark, RE
- Patel, A
- Mistrik, M
- McQuaker, G
- Chevallier, P
- Zuckerman, T
- Anagnostopoulos, A
- Nicolini, FE
- Chalandon, Y
- Yakoub-Agha, I
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Cita
Michallet,M,Sobh,M,Hazelaar,S,Apperley,J,Milpied,N,Labussiere,H,Blaise,D et al. Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP. 45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT). 2019. Frankfurt. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND:SPRINGERNATURE. 2019 p.p. 201-202.